Growth factors as treatment options for intestinal inflammation

Brian K. Dieckgraefe, Joshua R. Korzenik, Shrikant Anant

Research output: Chapter in Book/Report/Conference proceedingConference contributionpeer-review

21 Scopus citations


On the basis of several studies that have been completed to date, some growth factors appear promising for the treatment of inflammatory bowel disease: keratinocyte-like growth factor-2 (KGF-2), epidermal growth factor (EGF) enemas used in combination with oral mesalamine, somatropin (human growth hormone), and sargramostim (recombinant human GM-CSF). The results of these studies are highlighted and suggest that new insights into the regulation of intestinal immunity may provide effective synergistic or single-agent treatment alternatives to immunosuppression for inflammatory bowel disease. These data focus on the reparative components of mucosal homeostasis.

Original languageEnglish
Title of host publicationInflammatory Bowel Disease
Subtitle of host publicationGenetics, Barrier Function, Immunologic Mechanisms, and Microbial Pathways
PublisherBlackwell Publishing Inc.
Number of pages7
ISBN (Print)1573315680, 9781573315685
StatePublished - 2006

Publication series

NameAnnals of the New York Academy of Sciences
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632


  • Crohn's disease
  • Growth factors
  • Inflammatory bowel disease
  • Sargramostim


Dive into the research topics of 'Growth factors as treatment options for intestinal inflammation'. Together they form a unique fingerprint.

Cite this